Key points:
Anatara’s Detach™ reduced piglet mortality by 47.8%
Detach™ increased weaning weight of piglets by 5.2%
Data is consistent with earlier successful registration trials on commercial pig farms and supports renewed registration
BRISBANE, 18th February 2015: Anatara Lifesciences (ASX:ANR) is pleased to announce positive results from the first Australian field trial of its lead product DetachTM, a non-antibiotic natural product to prevent and treat diarrhoea in piglets. The trial was conducted on a commercial pig farm in Northern Victoria, and the data obtained will be used to support Anatara’s application to register DetachTM for sale in Australia with the Australian Pesticides and Veterinary Medicines Authority (APVMA).
The farm had a history of problems with pre-weaning diarrhoea, otherwise known as scour. Current approaches such as vaccines as well as antibiotics had failed to adequately control the problem.
There were 21 litters treated with DetachTM (233 piglets), while 23 litters were administered a placebo (229 piglets) in a randomised and blinded study. The trial investigated the incidence of death and scour, morbidity (or piglet clinical condition), antibiotic use as well as weight gains and found
:DetachTM significantly reduced piglet mortality by 47.8%. There were 19 piglets treated with DetachTM that died compared with 36 control piglets.
DetachTM reduced severe morbidity, or life threatening disease. In the control group, there were 38 morbid piglets, of which 36 died, compared with 28 morbid DetachTM piglets of which 19 died.
DetachTM increased the average weight of each piglet at weaning by 210g (or 5.2%). The increase in average daily weight gain to weaning was 5.3%. More detail on this trial is in the attached Appendix.
Anatara Chief Scientific Officer, Dr Tracey Mynott said: “The results from this trial reproduces our findings from our earlier registration trials where Detach™ was proven to be safe and effective in several thousand piglets on commercial pig farms. In these early trials, as in the current trial, DetachTM significantly reduced mortality, and improved piglet weight gains which provides an economic benefit to the farmer.”
Anatara will now focus on completing additional registration trials, as well as scaling up its activities for registration of DetachTM in Europe and the USA. Subject to successful field trials and regulatory approval, Anatara plans to launch Detach™ in Australia in 2016, and then launch in the EU and USA in 2017.
Dr Roger Campbell, CEO of the government supported Cooperative Research Centre for High Integrity Australian Pork (Pork CRC) commented, “The results of this trial are encouraging and support our view that Detach™ could provide a significant benefit to Australian pork producers. The Pork CRC remains keen to work closely with Anatara in investigating Detach™ in Pork CRC supported studies”.
Dr Mel Bridges, Chairman said “We are excited that the latest DetachTM field trials reinforce what earlier trials found. This is an important milestone for Anatara and validates our belief that DetachTM will become a valuable tool in producing healthy pigs and generating significant economic returns for farmers”.
”Since listing in October 2014 the Anatara team has worked diligently on delivering its key milestones. We are confident in our ability and capability to scale up manufacturing to meet with both the Australian and global demands,” Dr Bridges added.
For more information please contact:
General inquiries
Media inquiries
Mel Bridges
Gavin Lower
Chairman, Anatara Lifesciences
Buchan Consulting
+61 (0) 413 051 600
03 8866 1215
melbridges@parmacorp.com glower@buchanwe.com.au
About Anatara Lifesciences
Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Help employers find you! Check out all the jobs and post your resume.
BRISBANE, 18th February 2015: Anatara Lifesciences (ASX:ANR) is pleased to announce positive results from the first Australian field trial of its lead product DetachTM, a non-antibiotic natural product to prevent and treat diarrhoea in piglets. The trial was conducted on a commercial pig farm in Northern Victoria, and the data obtained will be used to support Anatara’s application to register DetachTM for sale in Australia with the Australian Pesticides and Veterinary Medicines Authority (APVMA).
The farm had a history of problems with pre-weaning diarrhoea, otherwise known as scour. Current approaches such as vaccines as well as antibiotics had failed to adequately control the problem.
There were 21 litters treated with DetachTM (233 piglets), while 23 litters were administered a placebo (229 piglets) in a randomised and blinded study. The trial investigated the incidence of death and scour, morbidity (or piglet clinical condition), antibiotic use as well as weight gains and found
:
Anatara Chief Scientific Officer, Dr Tracey Mynott said: “The results from this trial reproduces our findings from our earlier registration trials where Detach™ was proven to be safe and effective in several thousand piglets on commercial pig farms. In these early trials, as in the current trial, DetachTM significantly reduced mortality, and improved piglet weight gains which provides an economic benefit to the farmer.”
Anatara will now focus on completing additional registration trials, as well as scaling up its activities for registration of DetachTM in Europe and the USA. Subject to successful field trials and regulatory approval, Anatara plans to launch Detach™ in Australia in 2016, and then launch in the EU and USA in 2017.
Dr Roger Campbell, CEO of the government supported Cooperative Research Centre for High Integrity Australian Pork (Pork CRC) commented, “The results of this trial are encouraging and support our view that Detach™ could provide a significant benefit to Australian pork producers. The Pork CRC remains keen to work closely with Anatara in investigating Detach™ in Pork CRC supported studies”.
Dr Mel Bridges, Chairman said “We are excited that the latest DetachTM field trials reinforce what earlier trials found. This is an important milestone for Anatara and validates our belief that DetachTM will become a valuable tool in producing healthy pigs and generating significant economic returns for farmers”.
”Since listing in October 2014 the Anatara team has worked diligently on delivering its key milestones. We are confident in our ability and capability to scale up manufacturing to meet with both the Australian and global demands,” Dr Bridges added.
For more information please contact:
General inquiries
Media inquiries
Mel Bridges
Gavin Lower
Chairman, Anatara Lifesciences
Buchan Consulting
+61 (0) 413 051 600
03 8866 1215
melbridges@parmacorp.com glower@buchanwe.com.au
About Anatara Lifesciences
Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Help employers find you! Check out all the jobs and post your resume.
